Since the overwhelming majority of post-ACS patients in ODYSSEY Outcomes had PCI as part of their ACS management, what have we learned about the safety and efficacy of alirocumab in this stent-rich population of high-risk patients?

Since the overwhelming majority of post-ACS patients in ODYSSEY Outcomes had PCI as part of their ACS management, what have we learned about the safety and efficacy of alirocumab in this stent-rich population of high-risk patients?

Since the overwhelming majority of post-ACS patients in ODYSSEY Outcomes had PCI as part of their ACS management, what have we learned about the safety and efficacy of alirocumab in this stent-rich population of high-risk patients?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Andreas Zeiher, MD

Andreas Zeiher, MD

Chairman of Medicine
Department of Cardiology, Angiology, and Nephrology
J. W. Goethe University
Frankfurt, Germany